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Hsa-miR-224-5p (miR-224) is a tumor-related miRNA, which targets the expression of several Kallikrein 
(KLK) gents. The present study aims to analyze miR-224 expression in prostate cancer (CaP) cancer and to 
ZtTJr 7 ^ t , c s ' g " l f i c a n c c · Snap - frozen tissue samples were obtained from a well-characterized 
Ξ Î 5 X K K 1 ? ? ? h ^ C r p , , a s i a ( B P H > P a t i e n , s · M i R-224 expression levels were measured 
using qPCRafter the isolation, polyadenylation and reverse transcription of total RNA via a poly(T) 
adapter. MiR-224 was found to be downregulated in CaP compared to BPH patients (p<0 001 ) The 
expression levels of miR-224 were also gradually decreased in advanced pathological stage and high 
Gleason score CaP tumors (all ρ values <0.05). MiR-224 expression was associated with improved 
k l i n Ì Z T E S " " ? * ! ? S U r v u i v a , o r C a P P a t i e n t s (HR=0.314, ρ = 0.013). Our data reveal that the 
kalhkrem-targetmg m,R-224 can be vtewed as a potential prognostic biomarker for prostate cancer patients. 
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Stimulation of the enzymatic activity of kallikrein-related peptidase 3 (KLK3, also known as prostate 
specific antigen, PSA) may be beneficial for patients with prostate cancer due to the antiangiogenic activity 
denied Γ4 ,„K III "if!, * *T ^ ^ * ^ ^ ™ · T h e m0St P 0 l c n t « · "* ' 
denoted C4 and B2, both of which increase the proteolytic activity of KLK3 several-fold at micromolar 
concentrattons. However, no small molecule compounds with comparable activity have been reported 
IrntnZl U S e °, I"' PueptÌdeS ÌS h i 8 h , y c h a l l e nS i nS· W i t h l h i s in ™nd we set out to construct synthetic 
protocols for replacing both internal and terminal disulfide bridges with more stable hydrocarbon isosteres 
We have synthesized several pscudopeptide analogs based on both the C4 and B2 peptides All of shese 
pseudopeptides show a significant stimulating effect on KLK3, the most potent ones shoving a more than 
two-Iold activation at a concentration of 20 μg/ml (13-14 μΜ). 
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The deregulation of several miRNAs in prostate cancer (PCa) provides a novel pool of candidate tumor 
markers. Using in silico approaches, we have identified hsa-miR-378a-3p (miR-378a) as a potential post-
transcnptional regulator of KLK2 and KLK4. The aim of the study is the evaluation of the clinical 
significance of miR-378a for the prediction of PCa patients' outcome. Prostate tissue specimens obtained 
from 73 PCa and 64 BPH patients. Following extraction, total RNA was polyadenylated and reverse 
transcribed using a poly(T) adapter. A SYBR-Green based qPCR assay was applied thereafter for the 
quantification of miR-378a levels. Although miR-378a levels were not significantly altered between PCa 
and BPH, a statistically strong downregulation of miR-378a was observed in higher Gleason score 
(p-0.018) and larger diameter (rs=-0.402; p=0.034) tumors, as well as in patients with elevated PSA serum 
levels (rs—0.365; pO.001). Moreover, Kaplan-Meier survival curves pointed out the significantly shorter 
disease-free survival (DFS) of the PCa patients with reduced miR-378a levels (p=0.034). Finally in high-
recurrence risk patients, the reduced miR-378a levels revealed to be an independent predictor of poor DFS 
(p-0.030). Our data highlight that miR-378a loss increases the risk for short-term relapse of the PCa 
patients. 
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KLK8, like other members of the KLK family, may prove to be a promising clinical tool for breast cancer 
(BC). The objective of this study was the quantification of KLK8 mRNA expression in BC tissues, and the 
initial determination of its clinical utility as a potential BC biomarker. Therefore, total RNA was isolated 
from 50 breast tumors and their matched normal adjacent tissues, cDNA was prepared and KLK8 mRNA 
expression analysis was performed by comparative Ct method. The mRNA levels of KLK8 were found to 
be significantly downregulated in BC specimens compared to non-cancerous counterparts (p=0 002) 
Furthermore, patients with metastatic BC showed significantly lower KLK8 expression compared to those 
with organ confined tumors (p=0.031). Moreover, KLK8 mRNA levels were found to be significantly 
increased in HER2-positive compared to HER2-negative BC (p=0.017). Additionally, a negative 
correlation was observed between KLK8 and PgR expression levels (rs= -0.352; p=0.048). On the contrary 
no significant relationship was observed between KLK8 mRNA levels and histological tumor grade, T N M ' 
stage, or ER status. Nevertheless, our preliminary analysis, which will be extended in a larger patients' 
cohort, proposes a possible tumor suppressor role of KLK8 in BC and demonstrate its biomarker potential 
for this malignancy. 
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